At the LSX USA Congress held in Boston on September 22 and 23, a clear theme emerged across life sciences financing, partnering and development discussions: the market has moved decisively toward focus, speed and meaningful data, and thoughtful use of AI is crucial at every step.
From platforms to clear paths: a shift in investor focus
Five years ago, venture capital firms often favored platform technologies with broad potential across multiple indications, targets or modalities, such as an MRNA delivery platform. The investment rationale centered on the possibility that a single underlying technology could support a pipeline of products and create several paths to value. While platform stories remain compelling in the right circumstances, investors have become more selective about how those stories translate into near-term milestones.
The emphasis is now more often on a "beacon" product: a lead program with a defined development path, a coherent regulatory strategy, and the ability to generate meaningful data quickly. A credible lead product, such as protein-replacement candidate for a specific indication, can demonstrate the value of the broader technology, reduce scientific and execution risk, and provide a sharper basis for financing discussions. The key question is no longer simply whether a platform could address many opportunities, but whether a company can identify the opportunity most likely to produce decisive data efficiently.
Rethinking the value inflection point
Biotech companies seeking venture financing were also advised that they should be aiming to raise enough capital to reach Phase 1b data rather than treating Investigational New Drug (IND) clearance as the principal value inflection point. An IND remains an important regulatory and operational milestone, but investors are likely to place greater weight on initial clinical data showing safety, tolerability and early evidence of biological or therapeutic effect in patients, even if it takes more funding to get there. Companies therefore need to align their financing strategy, trial design and milestone planning around the data package most likely to support the next financing event.
Artificial intelligence can be particularly valuable in supporting such prioritization. Used thoughtfully, AI tools can help companies analyze target biology, patient populations, competitive landscapes, clinical-trial feasibility and potential biomarkers. This can assist management teams in selecting a lead indication or product candidate where the scientific rationale is strongest and the path to a meaningful clinical readout is most direct. AI does not replace rigorous scientific judgment, but it may help companies make earlier and better-informed decisions about where to concentrate finite capital and development resources.
Medical devices: framing the go-to-market narrative
The calculus is different for medical-device companies. For devices, the relevant inflection point may not be Phase 1b data, and the investment case frequently depends on a fuller early-stage narrative. Investors may expect a company to articulate not only the clinical and regulatory pathway, but also a realistic manufacturing plan, supply-chain strategy, reimbursement approach and commercial proposition. Demonstrating how the product can be produced reliably, scaled economically and adopted within identified markets may be central to the financing story from the outset. AI can support a go-to-market strategy by improving market selection, evidence planning, commercial execution and post-launch learning.
Health tech and the expanding data landscape
Digital health is similarly expanding the range and volume of health-related data available to patients, providers, researchers and life sciences companies. Wearables can give individuals greater visibility into their own health and may support more continuous monitoring outside traditional clinical settings. Technologies designed to collect information about environmental conditions, behavior and other external health determinants may also contribute to a broader shift toward prevention-oriented healthcare solutions. The legal and compliance framework around those uses will remain critical, particularly in relation to data quality, consent, privacy, cybersecurity, clinical validation and appropriate claims.
AI governance adds complexity to strategic alliances
Finally, strategic alliances and partnerships may become more complicated where potential collaborators apply different internal protocols for data sharing, AI governance and acceptable AI use. AI may accelerate research and development, but it can also introduce difficult contracting issues concerning data ownership, training rights, model inputs and outputs, confidentiality, validation, liability, cybersecurity, and regulatory responsibilities. Differing organizational policies can slow negotiations even where the parties share a common scientific objective. Clear governance principles and early alignment on data and AI use may therefore be as important to a successful collaboration as the underlying technology itself.
The bottom line: disciplined sequencing with AI
The practical message from Boston was that companies may benefit from deploying AI to facilitate disciplined sequencing: identify the right beacon product, finance to the data milestone that matters, develop a credible end-to-end operational story and build regulatory, data and contracting considerations into the strategy early.
White & Case means the international legal practice comprising White & Case LLP, a New York State registered limited liability partnership, White & Case LLP, a limited liability partnership incorporated under English law and all other affiliated partnerships, companies and entities. This article is prepared for the general information of interested persons. It is not, and does not attempt to be, comprehensive in nature. Due to the general nature of its content, it should not be regarded as legal advice. © 2026 White & Case LLP
